Back
Halozyme Therapeutics Stock Price Chart
The Mysterious VC Firm Behind Nvidia's Secret Weapon
Details Here!
Buy
69
HALO
Halozyme Therapeutics
Last Price:
60.65
Seasonality Move:
16.49%
7 Day Trial
ALL ACCESS PASS
$
7
Write This Down: Tuesday at 2 p.m. ET!
Don't Miss Our LIVE Trade- Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and HALO is experiencing buying pressure, which is a positive indicator for future bullish movement.
Halozyme Therapeutics Price Chart Indicators
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 53.23 | Buy |
| 20-day SMA: | 52.65 | Buy |
| 50-day SMA: | 57.01 | Buy |
| 200-day SMA: | 48 | Buy |
| 8-day EMA: | 54.74 | Buy |
| 20-day EMA: | 53.97 | Buy |
| 50-day EMA: | 55.06 | Buy |
| 200-day EMA: | 50.17 | Buy |
Halozyme Therapeutics Technical Analysis Indicators
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.23 | Sell |
| Relative Strength Index (14 RSI): | 64.88 | Buy |
| Chaikin Money Flow: | 1076544 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (50.35 - 56.95) | Buy |
| Bollinger Bands (100): | (51.6 - 59.84) | Buy |
Halozyme Therapeutics Technical Analysis
| Oct 23 | Oct 24 | Oct 25 | Oct 28 | Oct 29 | Oct 30 | Oct 31 | Nov 1 | Nov 4 | Nov 5 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct | Nov | |||||||||
| 23 | 24 | 25 | 28 | 29 | 30 | 31 | 01 | 04 | 05 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Technical Analysis for Halozyme Therapeutics Stock
Is Halozyme Therapeutics Stock a Buy?
- Halozyme Therapeutics share price is 58.72 while HALO 8-day simple moving average is 53.23, which is a Buy signal.
- The stock price of HALO is 58.72 while Halozyme Therapeutics 20-day SMA is 52.65, which makes it a Buy.
- Halozyme Therapeutics 50-day simple moving average is 57.01 while HALO share price is 58.72, making it a Buy technically.
- HALO stock price is 58.72 and Halozyme Therapeutics 200-day simple moving average is 48.00, creating a Buy signal.
HALO Technical Analysis vs Fundamental Analysis
Buy
69
Halozyme Therapeutics (HALO)
is a Buy
Is Halozyme Therapeutics a Buy or a Sell?
-
Halozyme Therapeutics stock is rated a Buy
The current Halozyme Therapeutics [HALO] share price is $58.72. The Score for HALO is 69, which is 38% above its historic median score of 50, and infers lower risk than normal.
Halozyme Therapeutics Stock Info
Market Cap:
7.47B
Price in USD:
58.72
Share Volume:
1.1M
Halozyme Therapeutics 52-Week Range
52-Week High:
65.53
52-Week Low:
33.15
Buy
69
Halozyme Therapeutics (HALO)
is a Buy
Halozyme Therapeutics Share Price Forecast
-
What is the Halozyme Therapeutics stock price today?
The Halozyme Therapeutics stock price is 58.72 USD today. -
Will HALO stock go up or go down?
Halozyme Therapeutics> share price is forecast to RISE/FALL based on technical indicators -
Is Halozyme Therapeutics overvalued?
According to simple moving average, exponential moving average, oscillators, and other technical indicators, Halozyme Therapeutics is not overvalued.
Is Halozyme Therapeutics Stock a Buy?
- Halozyme Therapeutics share price is 58.72 while HALO 8-day exponential moving average is 54.74, which is a Buy signal.
- The stock price of HALO is 58.72 while Halozyme Therapeutics 20-day EMA is 53.97, which makes it a Buy.
- Halozyme Therapeutics 50-day exponential moving average is 55.06 while HALO share price is 58.72, making it a Buy technically.
- HALO stock price is 58.72 and Halozyme Therapeutics 200-day simple moving average is 50.17, creating a Buy signal.
Fundamental Analysis of Halozyme Therapeutics
Is Halozyme Therapeutics a good investment?
- Analysts estimate an earnings increase this quarter of $0.21 per share, a decrease next quarter of $0.00 per share, an increase this year of $1.35 per share, and an increase next year of $0.66 per share.
Technical Analysis of Halozyme Therapeutics
Should I short Halozyme Therapeutics stock?
- HALO Moving Average Covergence Divergence (MACD) indicator is -0.23, suggesting Halozyme Therapeutics is a Sell
- Halozyme Therapeutics Relative Strength Index (RSI) is 64.88, which suggest Halozyme Therapeutics is overbought
- The Bollinger Bands (25) for Halozyme Therapeutics is (50.35 - 56.95), which suggest Halozyme Therapeutics is a Buy
- The Bollinger Bands (100) for Halozyme Therapeutics is (51.6 - 59.84), which suggest Halozyme Therapeutics is a Buy
* Halozyme Therapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.